Trials / Active Not Recruiting
Active Not RecruitingNCT02852655
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Dana-Farber Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research study is studying an immunotherapy as a possible treatment for Glioblastoma.
Detailed description
PD-1 works to help tumor cells continue to grow and multiply. Pembrolizumab (MK-3475) is a humanized monoclonal antibody. Humanized monoclonal is an antibody that is designed to block the action of the receptor, PD-1. The FDA (the U.S. Food and Drug Administration) has not approved Pembrolizumab for Glioblastoma but it has been approved for other uses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-3475 |
Timeline
- Start date
- 2016-09-21
- Primary completion
- 2022-06-02
- Completion
- 2026-07-31
- First posted
- 2016-08-02
- Last updated
- 2026-03-20
- Results posted
- 2024-11-26
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02852655. Inclusion in this directory is not an endorsement.